Xing Ai
Research Subjects
Xing Ai has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- Changlin Yang
Dongtai Center for Disease Control and Prevention, Dongtai 224299, China
1 shared publication - Dongyi Zheng
Beijing HuaXin Hospital; Beijing, PR China
1 shared publication - Feng-Ji Luo
Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Hangzhou, 310003, China
1 shared publication - Fengcai Zhu
School of Public Health, National Vaccine Innovation Platform, Nanjing Medical University, Nanjing, China
1 shared publication - Hai-Lian Du
National Institute of Diagnostics and Vaccine Development in Infectious Diseases; School of Public Health; Xiamen University; Xiamen, P.R. China
1 shared publication - Han-Min Jiang
Dongtai Center for Disease Control and Prevention, Jiangsu, 224000, PR China
1 shared publication
Latest Publications
- Open Access
- 1 November 2013
- Published by Taylor & Francis in Human Vaccines & Immunotherapeutics
- Vol. 9 (11) , 2474-2479
Immunogenicity and safety of hepatitis E vaccine in healthy hepatitis B surface antigen positive adults
A recombinant hepatitis E vaccine, Hecolin®, has been proven safe and effective in healthy adults. As hepatitis B surface antigen (HBsAg) positive individuals have a higher risk of poor prognosis after super-infection with hepatitis E virus (HEV), the safety and immunogenicity of Hecolin® in this population should be assessed. The present study is an extending analysis of data from a large randomized controlled clinical trial of Hecolin®. Healthy participants (n = 14,065) without current or previous evidence of chronic liver disease were randomized to receive Hecolin® or placebo (hepatitis B vaccine) and donated their blood samples before vaccination and subsequently over 31 mo. Most of the adverse events were mild and comparable between participants with and without baseline hepatitis B surface antigen (HBsAg). No vaccine-related serious adverse events were reported. Rates of serious adverse events in HBsAg (+) or HBsAg (-) participants were also comparable between both groups. Almost all participants in the Hecolin® group seroconverted to anti-HEV one month after full vaccination. The antibody response rates and levels were similar in HBsAg (+) and HBsAg (-) participants (98.38%, 19.32 Wu/mL vs. 98.69%, 19.00 Wu/mL). The two-year antibody dynamics of HBsAg (+) participants overlapped perfectly with those of HBsAg (-) participants. In conclusion, the safety and immunogenicity of Hecolin® for HBsAg (+) adults is very similar to that for the general population.
- 1 November 2013
- Published by Taylor & Francis in Human Vaccines & Immunotherapeutics
- Vol. 9 (11) , 2474-2479
Open AccessImmunogenicity and safety of hepatitis E vaccine in healthy hepatitis B surface antigen positive adults
A recombinant hepatitis E vaccine, Hecolin®, has been proven safe and effective in healthy adults. As hepatitis B surface antigen (HBsAg) positive individuals have a higher risk of poor prognosis after super-infection with hepatitis E virus (HEV), the safety and immunogenicity of Hecolin® in this population should be assessed. The present study is an extending analysis of data from a large randomized controlled clinical trial of Hecolin®. Healthy participants (n = 14,065) without current or previous evidence of chronic liver disease were randomized to receive Hecolin® or placebo (hepatitis B vaccine) and donated their blood samples before vaccination and subsequently over 31 mo. Most of the adverse events were mild and comparable between participants with and without baseline hepatitis B surface antigen (HBsAg). No vaccine-related serious adverse events were reported. Rates of serious adverse events in HBsAg (+) or HBsAg (-) participants were also comparable between both groups. Almost all participants in the Hecolin® group seroconverted to anti-HEV one month after full vaccination. The antibody response rates and levels were similar in HBsAg (+) and HBsAg (-) participants (98.38%, 19.32 Wu/mL vs. 98.69%, 19.00 Wu/mL). The two-year antibody dynamics of HBsAg (+) participants overlapped perfectly with those of HBsAg (-) participants. In conclusion, the safety and immunogenicity of Hecolin® for HBsAg (+) adults is very similar to that for the general population.
- Open Access
- 1 November 2013
- Published by Taylor & Francis in Human Vaccines & Immunotherapeutics
- Vol. 9 (11) , 2311-2315
A randomized, controlled, blinded study of the safety and immunogenicity ofHaemophilus influenzaetype b conjugate vaccine injected at different intramuscular sites in Chinese infants
To compare the safety and immunogenicity of Haemophilus influenzae type b (Hib) conjugate vaccine administered via the vastus lateralis and deltoid muscles, 320 healthy Chinese infants 0.05). In addition, there were no significant differences in the rates of local and systemic reactions after the first and second vaccinations between the 2 injection sites for either age group (P > 0.05), but the rate of systemic reactions in the 2–5 mo group after the third vaccination via the vastus lateralis muscle was significantly lower than after deltoid vaccination (0% vs 8.57%; P < 0.05). Thus, administration via the vastus lateralis muscle is worth considering for Hib vaccination.
- 1 November 2013
- Published by Taylor & Francis in Human Vaccines & Immunotherapeutics
- Vol. 9 (11) , 2311-2315
Open AccessA randomized, controlled, blinded study of the safety and immunogenicity ofHaemophilus influenzaetype b conjugate vaccine injected at different intramuscular sites in Chinese infants
To compare the safety and immunogenicity of Haemophilus influenzae type b (Hib) conjugate vaccine administered via the vastus lateralis and deltoid muscles, 320 healthy Chinese infants 0.05). In addition, there were no significant differences in the rates of local and systemic reactions after the first and second vaccinations between the 2 injection sites for either age group (P > 0.05), but the rate of systemic reactions in the 2–5 mo group after the third vaccination via the vastus lateralis muscle was significantly lower than after deltoid vaccination (0% vs 8.57%; P < 0.05). Thus, administration via the vastus lateralis muscle is worth considering for Hib vaccination.